Delgado-Lamas JL, Garcés-Ruiz OM, Aguilar-López LB, Borjas-Gutiérrez C, Flores-Márquez MR, Luna-Zaizar H, Delgado-Chávez R

Language: Spanish
References: 20
Page: 193-198
PDF size: 74.19 Kb.

ABSTRACT

Objective: to show clinical and therapeutic findings in patients with diagnosis of acute megakaryoblastic leukemia (AML).
Methods: twenty four patients with diagnosis AML was carried out. Clinical, laboratory survey results and treatment response were studied. Nineteen patients had primary form and five secondary, attended during a period of eight years. The diagnosis was established by a highly clinical suspicious, with immunophenotype cytometry flow or/and bone biopsy with immunohistochemistry study which proves definitely AML.
Results: Fourteen were women, the median age was 43 years, 18 were treated with antineoplasic agents, ten obtained response, six complete and four partial. The response may improve with schemes with high dose of cytosine arabinoside.
Conclusions: our results with the treatment showed that 27 % patients are alive under maintenance treatment long 18 months. The allogeneic bone marrow transplant seems to be one more option in long term.

REFERENCES

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7): a report of the French-American-British Cooperative Group. Ann Intern Med 1985;103(3):460-462.

2. Athale UH, Razzouk BI, Raimondi SC, Tong X, Behm FG, Head RD, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution’s experience. Blood 2001;97(12):3727-3731.

3. Creutzig U, Ritter J, Vormoor J, Ludwig WD, Niemeyer C, Reinisch I, et al. Myelodysplasia and acute myelogenous leukemia in Down syndrome. A report of 40 children of the AML-BFM study group. Leukemia 1996;10(11):1677-1686.

4. Ruiz-Argüelles GJ, Lobato-Mendizabal E, San Miguel JF, González M, Caballero MD, et al. Long-term treatment results for acute megakaryoblastic leukemia patients: a multicentric study. Br J Haematol 1992;82(4):671-675.

5. Paredes-Aguilera R, Romero-Guzmán L, López-Santiago N, Arana-Trejo R. Biology, clinical and hematologic features of acute megakaryoblastic leukemia in children. Am J Hematol 2003;73(2):71-80.

6. Crespo E, López-Karpovitch X, Abraham-Simón J, Lome-Maldonado C, Piedras J. Supervivencia, características clínicas y de laboratorio en leucemias megacarioblásticas de novo y secundaria. Rev Invest Clin 2003:55(5):494-501.

7. Pagano I, Pulsoni A, Vignetti M, Mele L, Fianchi L, Petti MC, et al. Acute megakaryoblastic leucemia: experience of GIMEMA trials. Leukemia 2002; 16(9):1622-1626.

8. Jaffe ES, Harris NL, Stein H, Vardiman JW; World Health Organization. Classification of tumors. Tumors of haematopietic and lymphoid tissues. Lyon, France: IARC Press; 2001.

9. Tallman MS, Neuberg D, Bennett JM, Francois CJ, Paietta E, Wiernik PH, et al. Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood 2000;96(7):2405-2411.

10. Windebank KP, Tefferi A, Smithson W, Li CY, Solberg LA, Priest JR, et al. Acute megakaryocytic leukemia (M7) in children. Mayo Clin Proc 1989;64(11):1339-1351.

11. Dastugue N, Lafage-Pochitaloff M, Pagés MP, Radford I, Bastard C, Talmant P, et al. Cytogenetic profile of childhood and adult megakaryoblastic leucemia (M7): a study of the Groupe Francais de Cytogénétique Hématologique. Blood 2002;100 (2):618-626.

12. Ma Z, Morris SW, Valentine V, Li M, Herbrick JA, Cui X, Bouman D, et al. Fusion of the novel genes, RBM15 and MKL1, in the t(1:22)(p13q13) of acute megakaryoblastic leukemia. Nature Gen 2001;28 (3):220-221.

13. Baüermeister DE. Quantitation of bone marrow reticulin—a normal range. Am J Clin Pathol 1971; 56(1):24-31.

14. Castro-Malaspina H, Rabellino EM, Yen A, Nachman RL, Moore MA. Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood 1981;57(4):781-787.

15. Kitagawa M, Yoshida S, Ishige I, et al. Immunolocalization of platelet derived growth factor, transforming growth factor-beta and fibronectin in acute megakaryoblastic leukemia manifestating tumor formation. Hum Pathol 1994;25(7):723-726.

16. Orazi A, O’Malley DP, Jiang J, Vance GH, Thomas J, Czader M, et al. Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia. Modern Pathol 2005:18(5): 603-614.

17. Hirose Y, Masaki Y, Shimoyama K, Sugai S, Nojima T. Granulocytic sarcoma of megakaryoblastic differentiation in the lymph nodes terminating as acute megakaryoblastic leukemia in a case of chronic idiopathic myelofibrosis persisting for 16 years. Eur J Haematol 2001;67(3):194-198.

18. Garderet L, Labopin M, Gorin NC, Polge E, Baruchel A, Meloni G, et al. Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2005; 105(1):405-409.

19. Radaelli F, Mazza R, Curioni E, Ciani A, Pomati M, Maiolo AT. Acute megakaryocytic leukemia in essential thrombocythemia: an unusual evolution? Eur J Haematol 2002;69(2):108-111

20. Liesveld LJ, Lichtman MA. Acute myelogenous leukemia. En: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, editores. Williams Hematology. Seventh edition. New York: McGraw Hill; 2006. p. 1183-1236.